184 related articles for article (PubMed ID: 36938723)
1. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract][Full Text] [Related]
2. CC Chemokine Receptors in Lung Adenocarcinoma: The Inflammation-Related Prognostic Biomarkers and Immunotherapeutic Targets.
Liu F; Wu H
J Inflamm Res; 2021; 14():267-285. PubMed ID: 33574689
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
Front Oncol; 2021; 11():711402. PubMed ID: 34497764
[TBL] [Abstract][Full Text] [Related]
4. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
5. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
[TBL] [Abstract][Full Text] [Related]
6. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
Front Oncol; 2019; 9():1555. PubMed ID: 32117786
[No Abstract] [Full Text] [Related]
7. Functions of CXC chemokines as biomarkers and potential therapeutic targets in the hepatocellular carcinoma microenvironment.
Wang J; Zhang C; Chen X; Li Y; Li A; Liu D; Li F; Luo T
Transl Cancer Res; 2021 May; 10(5):2169-2187. PubMed ID: 35116536
[TBL] [Abstract][Full Text] [Related]
8. CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment.
Zhou X; Peng M; He Y; Peng J; Zhang X; Wang C; Xia X; Song W
Front Oncol; 2021; 11():619003. PubMed ID: 33767987
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis.
Situ Y; Lu X; Cui Y; Xu Q; Deng L; Lin H; Shao Z; Chen J
Biomed Res Int; 2022; 2022():5137301. PubMed ID: 36246978
[TBL] [Abstract][Full Text] [Related]
10. Identification of Therapeutic Targets and Prognostic Biomarkers among Genes from the Mediator Complex Family in the Hepatocellular Carcinoma Tumour-Immune Microenvironment.
Tan W; Peng S; Li Z; Zhang R; Xiao Y; Chen X; Zhu J; Li B; Lv X
Comput Math Methods Med; 2022; 2022():2021613. PubMed ID: 35069777
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance and Therapeutic Target of CXC Chemokines in the Microenvironment of Lung Adenocarcinoma.
Wang K; Li R; Zhang Y; Qi W; Fang T; Yue W; Tian H
Int J Gen Med; 2022; 15():2283-2300. PubMed ID: 35250303
[TBL] [Abstract][Full Text] [Related]
12. Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer.
Liu F; Wu H
J Inflamm Res; 2021; 14():97-114. PubMed ID: 33469338
[TBL] [Abstract][Full Text] [Related]
13. Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment.
Jiang Z; Xing C; Wang P; Liu X; Zhong L
Front Cell Dev Biol; 2021; 9():748269. PubMed ID: 34938730
[No Abstract] [Full Text] [Related]
14. Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis.
Wu C; Ma C; Yuan J; Zhou P
Math Biosci Eng; 2021 Sep; 18(6):8201-8222. PubMed ID: 34814296
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract][Full Text] [Related]
16. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
[TBL] [Abstract][Full Text] [Related]
19. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
Wang L; Peng JL
Sci Rep; 2023 Jul; 13(1):10755. PubMed ID: 37400463
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment.
Jin Y; Lin Q; Fei H; Xue L; Li L; Xi Q; Jiang H
J Oncol; 2021; 2021():8859554. PubMed ID: 33763130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
